DoD Researchers Collaborate on Universal Antibody Test for COVID-19

USAMRIID researchers Laura Prugar (blue mask), Kathleen Huie (print mask) and Nicole Josleyn (purple mask) use a microneutralization assay and a high-throughput fluorescent imaging system to determine levels of neutralizing antibody to SARS-CoV-2 in convalescent patients. Credit: John W. Braun Jr., USAMRIID VIO

Researchers from the U.S. Army Futures Command, in collaboration with Houston Methodist, Pennsylvania State University, and UT Austin, tested alternative ways to measure COVID-19 antibody level resulting in a process that is faster, easier and less expensive to use on a large scale. Their method holds promise for accurately identifying potential donors who have the best chance of helping infected patients through convalescent plasma therapy.

The researchers sought to find alternatives to measuring virus neutralization (VN) titers in COVID-19 survivors, as VN antibodies in the blood have been shown to correlate with levels of protective immunity. VN testing is not widely available as it is technically complex and requires days to set up, run and interpret.

Dr. Jimmy Gollihar, biochemist and biotechnologist for the U.S. Army Combat Capabilities Development Command’s Army Research Laboratory, explained the team’s approach to pursue a more accessible enzyme-linked immunosorbent assay (ELISA).

“ELISAs are standard assays that can be performed in almost any academic or medical laboratory,” Gollihar said. “This is important in emergency care centers treating critically ill patients. The assays can also be used for serological monitoring of the disease.”

Given the sense of urgency to find an effective treatment for COVID-19, CCDC ARL’s Dr. Jimmy Gollihar was one of only a few researchers given access to the laboratory at UT Austin, where he uses unique equipment to fervently develop a synthetic biology-based approach to a neutralizing antibody therapy, as shown here. Credit: U.S. Army

The researchers examined the relationship of the anti-spike ectodomain, or ECD, and anti-receptor binding domain, or RBD, antibody titers in the bloodstream. The spike ECD and RBD proteins are components of the much-talked-about spike protein made by SARS-CoV-2 and are critical to how the virus enters the body, spreads and causes COVID-19 disease.

Live VN testing was conducted in collaboration with Dr. John Dye at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) under Biosafety Level 3 biocontainment conditions. Their work determined that the relative amount of antibody in the bloodstream of COVID-19 patients is linked to their ability to control viral infection; essentially, the more severe the disease, the higher the levels of neutralizing antibody present. This information provides potential benchmarks for a clinical product for convalescent plasma treatment studies; it could also be used to assess how well a vaccine recipient may respond to a subsequent infection.

The researchers found that the ELISA tests had an 80 percent or greater probability of predicting VN titers at or above the Food and Drug Administration-recommended levels for COVID-19 convalescent plasma.

“In all, we discovered that high titer ELISAs correlate well to virus neutralization and can be used as a surrogate for screening convalescent plasma,” Gollihar said.

In addition, the researchers found that convalescent donors maintain high levels of immunity over the course of many weeks, and that frequent plasma donations did not cause a significant decrease in antibody or virus neutralization levels.

Perhaps most surprising, the researchers said, is that they identified 27 individuals from the surveillance cohort with high enough antibody titers to indicate that some asymptomatic individuals may have plasma suitable for therapeutic use and may have a degree of relative immunity against SARS-CoV-2.

“This collaboration between the Army, Houston Methodist and our partners in academia shows the incredible diversity of complementary capabilities we can deploy in responding to a worldwide pandemic,” Dye said.

Funding from the National Institutes of Health, the Fondren Foundation, the National Institute of Allergy and Infectious Diseases, the Army Research Office, Houston Methodist Hospital, Houston Methodist Infectious Diseases Research Fund, Houston Methodist Research Institute and seed funding from the Huck Institutes of the Life Sciences for the studies at Penn State, together with the Huck Distinguished Chair in Global Health award supported this study. The CARES Act with programmatic oversight from the Military Infectious Diseases Research Program also supported this work.

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization, Journal of Clinical Investigation. 10 September 2020.

SARS, MERS, COVID-19: Repurposing Drugs for a Pan-Coronavirus Treatment

Biodefense Vaccine Development

Until a Coronavirus Vaccine is Ready, Pneumonia Vaccines May Reduce Deaths from COVID-19